Stock Track | CRISPR Therapeutics Soars 6.79% Pre-market on Chardan Capital's Buy Rating, Despite Mixed Analyst Views

Stock Track

May 07, 2025

CRISPR Therapeutics AG (CRSP) stock surged 6.79% in pre-market trading on Wednesday, following a positive analyst rating from Chardan Capital. The gene-editing company's shares received a boost after Chardan Capital maintained its Buy rating on the stock, signaling confidence in the company's potential.

The strong pre-market performance comes amid mixed analyst opinions. While Chardan Capital reaffirmed its bullish stance, Wells Fargo analyst Yanan Zhu maintained a Hold rating on CRISPR Therapeutics. This divergence in analyst views highlights the complex landscape of the gene-editing sector and the varying assessments of CRISPR Therapeutics' growth prospects and challenges.

Investors appear to be favoring the more optimistic outlook, as evidenced by the significant pre-market rally. The stock's movement also aligns with a broader trend of rising medical AI stocks, with CRISPR Therapeutics having gained 3% in overnight trading according to earlier reports. As the market opens, all eyes will be on whether CRISPR Therapeutics can maintain this momentum and how it navigates the balance between its growth potential and profitability challenges highlighted by analysts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1135613893"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135613893\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135613893?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 18:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135613893","market":"sg","top_or_hot":-1,"title":"Stock Track | CRISPR Therapeutics Soars 6.79% Pre-market on Chardan Capital's Buy Rating, Despite Mixed Analyst Views","media":"Stock Track","content":"<p>CRISPR Therapeutics AG (CRSP) stock surged 6.79% in pre-market trading on Wednesday, following a positive analyst rating from Chardan Capital. The gene-editing company's shares received a boost after Chardan Capital maintained its Buy rating on the stock, signaling confidence in the company's potential.</p>\n\n<p>The strong pre-market performance comes amid mixed analyst opinions. While Chardan Capital reaffirmed its bullish stance, Wells Fargo analyst Yanan Zhu maintained a Hold rating on CRISPR Therapeutics. This divergence in analyst views highlights the complex landscape of the gene-editing sector and the varying assessments of CRISPR Therapeutics' growth prospects and challenges.</p>\n\n<p>Investors appear to be favoring the more optimistic outlook, as evidenced by the significant pre-market rally. The stock's movement also aligns with a broader trend of rising medical AI stocks, with CRISPR Therapeutics having gained 3% in overnight trading according to earlier reports. As the market opens, all eyes will be on whether CRISPR Therapeutics can maintain this momentum and how it navigates the balance between its growth potential and profitability challenges highlighted by analysts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CRISPR Therapeutics Soars 6.79% Pre-market on Chardan Capital's Buy Rating, Despite Mixed Analyst Views</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CRISPR Therapeutics Soars 6.79% Pre-market on Chardan Capital's Buy Rating, Despite Mixed Analyst Views\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-07 18:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CRISPR Therapeutics AG (CRSP) stock surged 6.79% in pre-market trading on Wednesday, following a positive analyst rating from Chardan Capital. The gene-editing company's shares received a boost after Chardan Capital maintained its Buy rating on the stock, signaling confidence in the company's potential.</p>\n\n<p>The strong pre-market performance comes amid mixed analyst opinions. While Chardan Capital reaffirmed its bullish stance, Wells Fargo analyst Yanan Zhu maintained a Hold rating on CRISPR Therapeutics. This divergence in analyst views highlights the complex landscape of the gene-editing sector and the varying assessments of CRISPR Therapeutics' growth prospects and challenges.</p>\n\n<p>Investors appear to be favoring the more optimistic outlook, as evidenced by the significant pre-market rally. The stock's movement also aligns with a broader trend of rising medical AI stocks, with CRISPR Therapeutics having gained 3% in overnight trading according to earlier reports. As the market opens, all eyes will be on whether CRISPR Therapeutics can maintain this momentum and how it navigates the balance between its growth potential and profitability challenges highlighted by analysts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRSP","symbol_name":"CRISPR Therapeutics AG","start_time":0,"source_url":"","article_id":"1135613893","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135613893","pubTimestamp":1746615390,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CRISPR Therapeutics AG  stock surged 6.79% in pre-market trading on Wednesday, following a positive analyst rating from Chardan Capital. The gene-editing company's shares received a boost after Chardan Capital maintained its Buy rating on the stock, signaling confidence in the company's potential.The strong pre-market performance comes amid mixed analyst opinions. While Chardan Capital reaffirmed its bullish stance, Wells Fargo analyst Yanan Zhu maintained a Hold rating on CRISPR Therapeutics. T","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRSP":"CRISPR Therapeutics AG"},"translate_title":"尽管分析师观点不一，但Chardan Capital给予CRISPR Therapeutics买入评级，股价盘前飙升6.79%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1},"content_text":"CRISPR Therapeutics AG (CRSP) stock surged 6.79% in pre-market trading on Wednesday, following a positive analyst rating from Chardan Capital. The gene-editing company's shares received a boost after Chardan Capital maintained its Buy rating on the stock, signaling confidence in the company's potential.\nThe strong pre-market performance comes amid mixed analyst opinions. While Chardan Capital reaffirmed its bullish stance, Wells Fargo analyst Yanan Zhu maintained a Hold rating on CRISPR Therapeutics. This divergence in analyst views highlights the complex landscape of the gene-editing sector and the varying assessments of CRISPR Therapeutics' growth prospects and challenges.\nInvestors appear to be favoring the more optimistic outlook, as evidenced by the significant pre-market rally. The stock's movement also aligns with a broader trend of rising medical AI stocks, with CRISPR Therapeutics having gained 3% in overnight trading according to earlier reports. As the market opens, all eyes will be on whether CRISPR Therapeutics can maintain this momentum and how it navigates the balance between its growth potential and profitability challenges highlighted by analysts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}